Αρχική World News Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection... World News Switching to Camizestrant While Continuing a CDK4/6 Inhibitor After ESR1 Mutation Detection Prolongs PFS in ER-positive, HER2-negative ABC Από Ogkologos - 9 Ιουλίου, 2025 952 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SERENA-6 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Cancer and the Holidays 3 Δεκεμβρίου, 2021 EMA Adopts a New Pharmaceutical Form of Selumetinib 16 Δεκεμβρίου, 2025 2026 Heine H. Hansen Award Recipient Announced 3 Φεβρουαρίου, 2026 Utility of a Methylation-Based Multicancer Early Detection Test in Identifying Whom... 4 Ιουλίου, 2023 Φόρτωση περισσοτέρων HOT NEWS A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with... Are differences in treatment driving variation in ovarian cancer survival internationally? “After a fire and a pandemic, it felt amazing to finish... How to Be Brave When Your Parent Has Cancer: A Kid’s...